Synaptogenix, Inc., an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, commented on the positive Phase 3 trial results for Lecanemab announced last...
Cell coding company bit.bio has announced an expansion to its product portfolio - ioGlutamatergic Neurons TDP-43M337V disease model and early access to its ioMicroglia...
CP Kelco, a global leader of nature-based ingredient solutions that is owned by J.M. Huber Corporation, and ExoPolymer, Inc., a biotechnology startup company focused...
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that its U.S. joint venture (JV) partner...
Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that...
